- Home
- SONN vs PRFX Comparison
SONN vs PRFX Comparison
Compare SONN & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- PRFX
- Stock Information
- Founded
- SONN N/A
- PRFX 2007
- Country
- SONN United States
- PRFX Israel
- Employees
- SONN N/A
- PRFX N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- PRFX Health Care
- Exchange
- SONN Nasdaq
- PRFX Nasdaq
- Market Cap
- SONN 2.5M
- PRFX 2.7M
- IPO Year
- SONN N/A
- PRFX 2020
- Fundamental
- Price
- SONN $1.62
- PRFX $3.20
- Analyst Decision
- SONN Strong Buy
- PRFX Hold
- Analyst Count
- SONN 2
- PRFX 1
- Target Price
- SONN $38.00
- PRFX N/A
- AVG Volume (30 Days)
- SONN 282.7K
- PRFX 1.1M
- Earning Date
- SONN 02-12-2025
- PRFX 08-15-2024
- Dividend Yield
- SONN N/A
- PRFX N/A
- EPS Growth
- SONN N/A
- PRFX N/A
- EPS
- SONN N/A
- PRFX N/A
- Revenue
- SONN $18,626.00
- PRFX N/A
- Revenue This Year
- SONN N/A
- PRFX N/A
- Revenue Next Year
- SONN N/A
- PRFX N/A
- P/E Ratio
- SONN N/A
- PRFX N/A
- Revenue Growth
- SONN N/A
- PRFX N/A
- 52 Week Low
- SONN $1.41
- PRFX $0.43
- 52 Week High
- SONN $18.72
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- SONN 42.90
- PRFX 49.57
- Support Level
- SONN $1.64
- PRFX $2.87
- Resistance Level
- SONN $2.05
- PRFX $3.58
- Average True Range (ATR)
- SONN 0.17
- PRFX 0.51
- MACD
- SONN 0.03
- PRFX -0.02
- Stochastic Oscillator
- SONN 24.59
- PRFX 11.76
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.